Exelixis | EXEL - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 332.22M 29.22M 2026-09
Agios Pharmaceuticals USD 77.59M 7.37M 2026-09
Akebia Therapeutics USD 162.35M 1.48M 2026-09
Amgen USD 23.23B 2.27B 2026-09
AstraZeneca USD 31.27B 286M 2026-09
Bayer EUR 29.4B 2.87B 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Cytokinetics USD 353.42M 171.99M 2026-09
Eisai JPY 371.5B 22.14B 2026-09
Eli Lilly USD 47B 745M 2026-09
Exelixis USD 411.88M 49.95M 2026-09
Genmab DKK 1.14B 38M 2026-06
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Incyte USD 1.44B 125.72M 2026-09
Ionis Pharmaceuticals USD 435.29M 119.65M 2026-09
MacroGenics USD 107.23M 1.58M 2026-09
Merck USD 28.8B 1.07B 2026-09
Moderna USD 2.03B 506M 2026-09
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Novartis USD 32.52B 777M 2026-09
Pfizer USD 31.73B 920M 2026-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 31.93B 1.92B 2026-06
Takeda JPY 2.6T 161B 2026-09
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Xencor USD 76.27M 5.6M 2026-09